Intragastric prosthesis for the treatment of morbid obesity

ABSTRACT

A porous weave of bioabsorbable filaments having an open mesh configuration is formed into an oblate shape having dimensions greater than the esophageal opening and gastric outlet of a stomach. The resulting prosthesis is deployed in the stomach and is of a size to be retained in the proximate portion thereof for exerting pressure on the upper fundus. The prosthesis limits the amount of food that may be held within the stomach, and exerts pressure on the fundus to create a sensation of being full, resulting in weight loss.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 10/795,491,filed Mar. 8, 2004, now U.S. Pat. No. 7,090,699, which is a continuationof application Ser. No. 10/057,469, filed Jan. 25, 2002, now U.S. Pat.No. 6,755,869, which is a continuation of application Ser. No.10/007,819, filed Nov. 9, 2001, now abandoned, the disclosures of whichare hereby expressly incorporated by reference.

FIELD OF INVENTION

The present invention pertains to a resilient, flexible, compressible,bio-compatible prosthesis insertable into the stomach to effect weightloss over a controlled period.

BACKGROUND

The incidence of obesity and its associated health-related problems havereached epidemic proportions in the United States. See, for example, P.C. Mun et al., “Current Status of Medical and Surgical Therapy forObesity” Gastroenterology 120:669-681 (2001). Recent investigationssuggest that the causes of obesity involve a complex interplay ofgenetic, environmental, psycho-behavioral, endocrine, metabolic,cultural, and socio-economic factors. Severe obesity is frequentlyassociated with significant comorbid medical conditions, includingcoronary artery disease, hypertension, type II diabetes mellitus,gallstones, nonalcoholic steatohepatitis, pulmonary hypertension, andsleep apnea.

Estimates of the incidence of morbid obesity are approximately 2% of theU.S. population and 0.5% worldwide. Current treatments range from diet,exercise, behavioral modification, and pharmacotherapy to various typesof surgery, with varying risks and efficacy. In general, nonsurgicalmodalities, although less invasive, achieve only relatively short-termand limited weight loss in most patients. Surgical treatments includegastroplasty to restrict the capacity of the stomach to hold largeamounts of food, such as by stapling or “gastric banding.” Othersurgical procedures include gastric bypass and gastric “balloons” which,when deflated, may be inserted into the stomach and then are distendedby filling with saline solution.

The need exists for cost effective, less invasive interventions for thetreatment of morbid obesity.

SUMMARY

This summary is provided to introduce a selection of concepts in asimplified form that are further described below in the DetailedDescription. This summary is not intended to identify key features ofthe claimed subject matter, nor is it intended to be used as an aid indetermining the scope of the claimed subject matter.

The present invention provides a novel system for treatment of morbidobesity by use of a bioabsorbable gastric prosthesis placed in thestomach through a minimally invasive procedure. The prosthesis takes upspace in the stomach so that the stomach can hold a limited amount offood, and preferably exerts pressure on the upper fundus to create asensation of being full. The material of the prosthesis can be selectedto degrade over a predetermined period and pass out of the patientwithout additional intervention.

In the preferred embodiment, the prosthesis is a porous weave ofbioabsorbable filaments having an open mesh configuration. Theprosthesis can be formed from a cylindrical stent, such as by revertingthe ends of the cylinder and joining them at the center. The filamentspreferably have memory characteristics tending to maintain an oblateshape with sufficient resiliency and softness so as not to undulyinterfere with normal flexing of the stomach or cause abrasion of themucus coat constituting the inner lining of the stomach. The prosthesismay be free floating in the stomach, but is shaped so as to be biasedagainst the upper fundus, or it may be tacked in position adjacent tothe fundus by bioabsorbable sutures.

DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of thisinvention will become more readily appreciated as the same become betterunderstood by reference to the following detailed description, whentaken in conjunction with the accompanying drawings, wherein:

FIG. 1 is a somewhat diagrammatic elevation of a stomach and adjacentparts of the alimentary canal, with the wall adjacent to the viewerpartially broken away to reveal an intragastric prosthesis in accordancewith the present invention;

FIG. 2 is a side elevation of a cylindrical stent from which aprosthesis in accordance with the present invention may be formed;

FIG. 3 is a side elevation of a prosthesis in accordance with thepresent invention, formed from the stent of FIG. 2; and

FIG. 4 is a diagrammatic elevation corresponding to FIG. 1, illustratinginsertion of a prosthesis in accordance with the present inventionthrough the esophagus and into the stomach.

DETAILED DESCRIPTION

The present invention provides a volume-filling prosthesis insertableinto the stomach for treatment of morbid obesity by taking up space inthe stomach to reduce its capacity and by exerting pressure to create asensation of being full, particularly on the upper fundus.

FIG. 1 illustrates a central portion of the alimentary canal includingthe distal segment of the esophagus 10, the stomach 12, and the duodenum14 (proximate segment of the small intestine). The esophagus 10 opensinto the stomach 12 toward the top of the lesser curvature 16 adjacentto the fundus 18. The pyloric part 20 of the stomach leads to theduodenum by way of the gastric outlet or pylorus 22 which forms thedistal aperture of the stomach and has an enclosing circular layer ofmuscle which is normally contracted to close the aperture but whichrelaxes to provide an open but restricted passage. Although subject tosubstantial variation in different individuals, representativedimensions for the stomach are approximately 8 cm long (fundus topylorus) by 5 cm wide (greatest distance between lesser and greatercurvatures), with the esophageal opening being approximately 2 cm indiameter and the pylorus having a maximum open diameter of about 2 cm.

In accordance with the present invention, an oblate, volume-fillingprosthesis 24 is held within the stomach, sized for reception in theproximate portion adjacent to the opening of the esophagus and fundus.Such prosthesis preferably is a porous body formed of a loose weave ofthin polymer filaments 26, having large spaces between filaments for anopen area of at least about 80%, preferably more than 90%, so as not toimpede the flow of gastric juices or other functioning in the stomach.The filaments 26 have substantial memory characteristics for maintainingthe desired oblate shape and size. However, the filaments preferably aresufficiently soft and flexible to avoid abrasion of the mucus coatforming the inner lining of the stomach and to enable normal flexing andshape changes. The size of the prosthesis 24 is substantially greaterthan the opening of the esophagus, at least about 3 cm in the narrowestdimension, preferably at least about 4 cm. The longer dimension of theoblate prosthesis is greater than 4 cm, preferably at least about 5 cmto prevent the prosthesis from free movement within the stomach. Thesize and shape of the prosthesis tend to maintain it in the positionindicated in FIG. 1, adjacent to the fundus 18 and remote from thepyloric part 20. Thus, while the prosthesis occupies a substantialportion of the volume of the stomach, preferably approximately one-halfthe volume, the prosthesis does not interfere with normal digestion offood, such as by gastric juices (hydrochloric acid and digestiveenzymes) nor with passage of food through the pyloric part 20 and itsopening 22 to the duodenum 14.

With reference to FIG. 2, the prosthesis can be formed from asubstantially cylindrical stent 28 having the desired porous weave andlarge open area. The filaments 26 and weave pattern are selected toachieve memory characteristics biasing the prosthesis to the cylindricalcondition shown. In the preferred embodiment, the opposite ends 30 ofthe stent are reverted, the end portions are rolled inward, and the endsare secured together such as by suturing. Alternatively, a disk of thesame pattern and material can be used in securing the reverted endstogether. The resiliency of the filaments tends to bulge the resultingprosthesis 26 outward to the desired oblate shape.

Prior to reversion of the ends, stent 28 in the condition shown in FIG.2 can be approximately 2-3 cm in diameter and approximately 8-10 cmlong, in a representative embodiment. The filaments can have a diameterof about 0.010 inch to about 0.25 inch. The filaments may be coated orimpregnated with other treating agents, such as appetite suppressants,or agents to decrease the likelihood of gastric problems, such asulcers, due to the presence of a foreign object. However, such problemsare unlikely due to the biocompatible nature and the resilientflexibility of the prosthesis.

It is preferred that the filaments 26 be formed of a bioabsorbablepolymer such as a polyglycolic acid polymer or polylactic acid polymer.Similar materials are used for some bioabsorbable sutures having“forgiving” memory characteristics and sufficient “softness” that tissueabrasion is inhibited. The absorption characteristics of the filaments26 can be selected to achieve disintegration of the prosthesis 26 withinthe range of three months to two years, depending on the severity ofobesity. In the preferred embodiment, the prosthesis will absorb andpass naturally from the stomach approximately 6 months after deployment.

Nonbioabsorbable materials may be used, such as Nitinol, which exhibitthe desired springiness but which would require that the prosthesis beretrieved. An advantage of the preferred, bioabsorbable embodiment ofthe invention is that delivery can be through the esophagus, with noadditional intervention being required.

With reference to FIG. 4, preferably from the condition shown in FIG. 3,the prosthesis 26 can be compressed to a generally cylindrical shapehaving a diameter of no more than about 2 cm such that the compressedprosthesis can be carried in a short (approximately 5 cm to 6 cm long)loading tube 32. The loading tube can be advanced along the esophagus bya central tube 34 of smaller diameter, under the visualization allowedby a conventional endoscope 36. The tube 34 can enclose a core wire 38to actuate a pusher mechanism 40 for ejecting the prosthesis 26 when theopening of the esophagus into the stomach has been reached. Theendoscope and deployment mechanism can then be retracted.

While the preferred embodiment of the invention has been illustrated anddescribed, it will be appreciated that various changes can be madetherein without departing from the spirit and scope of the invention.For example, while it is preferred that the prosthesis be sized forself-retention in the desired position in the stomach, it also may besecured in position by a few sutures applied endoscopically, preferablyin or adjacent to the fundus area of the stomach.

1. An intra-gastric prosthesis comprising an empty porous oblate bodyformed of a weave of flexible, resilient filaments and sized forreception in a stomach, the size of the oblate body, when deployed in astomach, being greater than the esophageal opening and the gastricoutlet for retention in the stomach.
 2. The prosthesis defined in claim1, in which the filaments are bioabsorbable, so that the prosthesis willpass from a stomach without surgical intervention after an approximatelypredetermined period.
 3. The prosthesis defined in claim 2, in which theapproximately predetermined period is 3 months to 2 years.
 4. Theprosthesis defined in claim 3, in which the approximately predeterminedperiod is about six months.
 5. The prosthesis defined in claim 1, inwhich the filaments form a body having an open area of at least 80%. 6.The prosthesis defined in claim 5, in which the filaments form a bodyhaving an open area of at least 90%.
 7. The prosthesis defined in claim1, in which the oblate body has a minimum diameter of at least 3 cm. 8.The prosthesis defined in claim 7, in which the oblate body has aminimum diameter of at least 4 cm.
 9. The prosthesis defined in claim 1,in which the oblate body has a long dimension greater than 4 cm.
 10. Theprosthesis defined in claim 9, in which the oblate body has a longdimension at least about 5 cm.
 11. The prosthesis defined in claim 1, inwhich the body is sized for reception in the proximate portion of thestomach adjacent to the fundus for applying pressure to the fundus. 12.The prosthesis defined in claim 1, in which the body is formed of agenerally cylindrical stent of the filaments with opposite ends of thestent reverted and secured together.
 13. The prosthesis defined in claim1, in which the filaments are coated or impregnated with a medicaltreating agent.
 14. The prosthesis defined in claim 1, in which the bodyis compressible to a generally cylindrical shape having a diameter of nomore than about 2 cm.
 15. The prosthesis defined in claim 14, andmechanism for deploying the body in a stomach, such mechanism includinga loading member for receiving the body in compressed condition, anadvancing member for moving the loading member along the esophagus, anda deployment mechanism for ejecting the body into the stomach wherebythe body expands due to memory characteristics of the filaments.
 16. Amethod of inducing weight loss in a patient, which comprises placinginto the stomach of the patient an empty porous oblate body formed of aweave of flexible, resilient filaments and sized for reception in astomach, the size of the oblate body, when deployed in a stomach, beinggreater than the esophageal opening and the gastric outlet for retentionin the stomach.
 17. The method defined in claim 16, in which thefilaments are bioabsorbable, so that the prosthesis will pass from astomach without surgical intervention after an approximatelypredetermined period.
 18. The method defined in claim 16, in which theapproximately predetermined period is 3 months to 2 years.
 19. Themethod defined in claim 16, in which the approximately predeterminedperiod is about six months.